Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Background: The emergence of antifungal resistance threatens effective treatment of invasive fungal infection (IFI). Invasive candidiasis is the most common health care–associated IFI. We evaluated the activity of fluconazole (FLU) against 20 788 invasive isolates of Candida (37 species) collected from 135 medical centers in 39 countries (1997–2016). The activity of anidulafungin, caspofungin, and micafungin (MCF) was evaluated against 15 308 isolates worldwide (2006–2016). Methods: Species identification was accomplished using phenotypic (1997–2001), genotypic, and proteomic methods (2006–2016). All isolates were tested using reference methods and clinical breakpoints published in the Clinical and Laboratory Standards Institute documents. Results: A decrease in the isolation of Candida albicans and an increase in the isolation of Candida glabrata and Candida parapsilosis were observed over time. Candida glabrata was the most common non–C. albicans species detected in all geographic regions except for Latin America, where C. parapsilosis and Candida tropicalis were more common. Six Candida auris isolates were detected: 1 each in 2009, 2013, 2014, and 2015 and 2 in 2016; all were from nosocomial bloodstream infections and were FLU-resistant (R). The highest rates of FLU-R isolates were seen in C. glabrata from North America (NA; 10.6%) and in C. tropicalis from the Asia-Pacific region (9.2%). A steady increase in isolation of C. glabrata and resistance to FLU was detected over 20 years in the United States. Echinocandin-R (EC-R) ranged from 3.5% for C. glabrata to 0.1% for C. albicans and C. parapsilosis. Resistance to MCF was highest among C. glabrata (2.8%) and C. tropicalis (1.3%) from NA. Mutations on FKS hot spot (HS) regions were detected among 70 EC-R isolates (51/70 were C. glabrata). Most isolates harboring FKS HS mutations were resistant to 2 or more ECs. Conclusions: EC-R and FLU-R remain uncommon among contemporary Candida isolates; however, a slow and steady emergence of resistance to both antifungal classes was observed in C. glabrata and C. tropicalis isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Historically this organism has been pan-susceptible to triazoles, echinocandins, and amphotericin B.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“In the US, fluconazole resistance rates range between 4–10%; rates are much higher in other parts of the world including Japan, Western Europe, and Latin America.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although relatively low levels of resistance for most Candida species have been described, the outcomes for candidemia remain poor, as high levels of mortality (15%-50%) have been associated with candida infections7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this Review, we explore the molecular mechanisms that contribute to antifungal drug resistance, with a focus on Candida spp., the most common cause of fungal infections in humans7.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [7]
Experimental — accuracy not yet measured
22 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“Sentinel surveillance programs designed to capture organisms and patient demographic data from representative sites spanning a larger geographical area and over a longer period of time serve to fill the gaps in time and space that are necessarily left by the more intensive and focused, yet intermittent, population-bas…”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12]; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs.”
BackgroundLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 2×
“S90 • OFID 2019:6 (Suppl 1) • Pfaller et al SENTRY Program Candida Surveillance (1997–2016) • OFID 2019:6 (Suppl 1) • S91 [93, 94], and emerging resistance mechanisms [20, 68] highlight the importance of local and global surveillance studies.”
BackgroundSelf-citationKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 1×
“Caspofungin, micafungin, and anidulafungin were approved for clinical use by the US Food and Drug Administration (FDA) in 2001, 2005, and 2006, respectively, and are now recommended as firstline agents for treating IC [50, 67].”
BackgroundCalderone, R. (2012) · ASM Press eBooks · Cited by 912
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citation
Research works printed but not linked: 4
- 38. CLSI. M27-S4. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: 4th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- 39. CLSI. M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
- 40. CLSI. M59. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- 63. Pfaller MA, Diekema DJ Azole antifungal drug cross-resistance: mechanisms epidemiology, and clinical significance. J Invasive Fungal Infect 2007; 1: 74– 92.
Cited by
Items 901–931 of 931
Reinhold, I., Ramírez, I., Chen, P., Chen, Y., Dhariwal, A., Lambourne, J., Agrawal, S. G., Bastida, M., Gudiol, C., Alfandari, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104194
Nasrallah, E. T., Magid, A., Stein, M., Gelman, E., Danino, D., Hadad, L., Ashkenazi‐Hoffnung, L., Mor, M., Sachs, N., Shechter, N., et al. (2026) · Journal of Fungi · doi:10.3390/jof12090695
Resistant Candida spp. in Healthy Individuals: Mapping a Surveillance Blind Spot
Alves, A. M. C. V., de Lima, L. F., Cruz, G. S., Leite, A. C. R. D. M., de Brito, É. H. S., Azevedo, N. F., & Rodrigues, C. F. (2026) · Microbiology Research · doi:10.3390/microbiolres17090184
Non-albicans Candida Species: Epidemiology and Antifungal Resistance
Bosan, M. A., Durrani, A. D., Faiz, A., Farooqi, J. Q., & Jabeen, K. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00542-1
Ortiz‐Prado, E., Vásconez-González, J., Cuenca, K. A., Núñez-Loor, F., Acosta-Muñoz, M. C., Mesias, D. A., Villarreal-Burbano, K. B., Arias-Intriago, M., & Izquierdo‐Condoy, J. S. (2026) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed11100279
Diagnostic approach of Fungal Pathogens associated with Nosocomial Infections
Surabhi Sharma, D. U. F., Farooq, U., Singh, S., & Sharma, V. (2025) · South Eastern European Journal of Public Health
Iqbad, M. Z., & Gupta, S. (2014) · Eurasian Journal of Analytical Chemistry
Characterization of Human Commensal Candida Albicans Hyphal Morphology
Williams, C. (2026) · Library, Museums and Press - UDSpace (University of Delaware)
Full Issue - Vol. 33, No. 1, Jan - Mar 2024
Editor Office (2024) · Infectious Diseases Journal of Pakistan
Harnessing environmental yeasts - Pichia kudriavzevii strain ZMUM_K002
Vajdič, T., & Erjavec, M. S. (2025) · University of Maribor digital library (University of Maribor)
Sharma, S., & Farooq, U. (2025) · Journal of Neonatal Surgery
Yousefi, P. S. M. (2026) · Iranian Journal of Microbiology · doi:10.18502/ijm.v18i5.22862
Logan, C., Allebone-Salt, P. E., Mazzella, A., Hemsley, C., Goodman, A. L., Ward, C., Fife, A., Schelenz, S., Abdolrasouli, A., & Bicanic, T. A. (2026) · UCL Discovery (University College London)
Echevarría, L. (2025) · International Journal of Nanotechnology and Allied Sciences
Zhu, C., Zhang, M., Wan, F., Wang, Z., Wang, S., Kang, Z., Tsui, C. K. M., Guo, J., Liu, N.-N., & Wu, W. (2026) · The Lancet Microbe · doi:10.1016/j.lanmic.2026.101509
Changes in age composition and epidemiology of candidaemia, Iceland, 2012 to 2023
Ásmundsdóttir, L. R., Bergthorsdottir, J. G., Steinarsson, A. O., & Gottfreðsson, M. (2026) · Eurosurveillance · doi:10.2807/1560-7917.es.2026.31.40.2600120
How do I manage candiduria: practical algorithms and remaining conundrums in 2026
Blez, D., Πανά, Ζ. Δ., Lampros, A., Benvenuto, D., Gaultier, S., Belan, M., Lachâtre, M., Richebé, P., Canouï, É., Rouges, C., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.08.011
Farooq, H., Qazi, R., Nizamuddin, S., Malik, N., Raza, A., Mansoor, M., Fazal, A., Irfan, M., & Sultan, F. (2026) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2026.26913
Kumar, D., Maheshwari, R. K., Thakuriya, R., & Awasthi, P. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.88s.53
Penea, C. A.-M. O., Melinte, V., Creţu, E., Holban, T. S., Radu, A. M., Văcăroiu, C. M., Cambrea, C. S., & Gheorghiţă, V. (2026) · Journal of Medicine and Life · doi:10.25122/jml-2026-0074
Yabalak, E., Demircan, A., Ayas, D., & Yabalak, E. (2026) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-026-04551-y
冯晓燕, Li, J., Li, S., Yang, L., & Li, K. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s649356
Ogba, O. M., Ibe, H., Inah, I. O., Akpan, N. G., Nyambi, E. S., & Obongha, E. E. (2026) · Studies in Fungi · doi:10.48130/sif-0026-0031
Quejada, L. F., de Almeida, R. M., Verícimo, M. A., Pacheco, P. A. F., & Faria, R. X. (2026) · Journal of Chemistry · doi:10.1155/joch/3054407
Vu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · doi:10.1371/journal.pgen.1009582.r002
Vazquez-Munoz, R., Thompson, A., Russell, J. T., Sobue, T., Zhou, Y., & Dongari-Bagtzoglou, A. (2022) · doi:10.3389/fmicb.2022.853762.s001
Asadzadeh, M., Ahmad, S., Al-Sweih, N., & Khan, Z. (2023) · doi:10.3389/fpubh.2023.1242622.s001
Fan, X., Tsui, C. K. M., Chen, X., Wang, P., Liu, Z.-J., & Yang, C.-X. (2023) · doi:10.3389/fmicb.2023.1125241.s001
Gaspar-Cordeiro, A., Amaral, C., Pobre, V., Antunes, W., Petronilho, A., Paixão, P., Matos, A. P., & Pimentel, C. (2022) · doi:10.3389/fmicb.2022.920574.s005
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N.
- Affiliations
- University of Iowa (US)
- The University of Adelaide (AU)
- JMI Laboratories (US)
- Corresponding author
- Pfaller, Michael A
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03
- Volume
- 6
- Issue
- Supplement_1
- Pages
- S79-S94
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC6419901
- OpenAlex
- W2922388167
- Semantic Scholar
- b99f36f4463b9afe6d2a0ab52eebb3f5e726f4c0
- Cited by
- 825
- References
- 114
- Citations by year
- 2026: 92 · 2025: 129 · 2024: 133 · 2023: 141 · 2022: 94 · 2021: 108 · 2020: 104 · 2019: 24
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- JMI Laboratories
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- invasive candidiasis, Candida species, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida auris, micafungin resistance, caspofungin, anidulafungin, Candida species distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.